Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Crinetics Pharmaceuticals Inc.
Grupo Espanol de Tumores Neuroendocrinos
Novartis
University of Alberta
Advanced Accelerator Applications
RayzeBio, Inc.
Rezolute